Market Place
Sourcing Support
T-knife Files Trial Application for Ph 1 ATLAS Trial for TK-6302
17 Nov 2025 //
GLOBENEWSWIRE
T-Knife Unveils Prame-Targeted TK-6302 Data At SITC Meeting
07 Nov 2025 //
GLOBENEWSWIRE
T-Knife To Present Four Prame-Targeted TK-6302 Data At SITC
30 Oct 2025 //
GLOBENEWSWIRE
T-Knife Therapeutics Showcases MyT Platform at ESGCT 2025
07 Oct 2025 //
GLOBENEWSWIRE
T-knife Therapeutics Appoints Christoph Broja to Board
01 Jul 2025 //
GLOBENEWSWIRE
T-knife Therapeutics Presents Preclinical Data at AACR Meeting
25 Apr 2025 //
GLOBENEWSWIRE
T-knife Therapeutics Announces Five Presentations at AACR Meeting
25 Mar 2025 //
GLOBENEWSWIRE
T-Knife Therapeutics Appoints Dr. Sophie Papa To Board
20 Feb 2025 //
GLOBENEWSWIRE
T-knife to Participate in 2 Investor Conferences in March
12 Feb 2025 //
GLOBENEWSWIRE
T-knife Therapeutics Announces the Appointment of Behzad Kharabi as CMO
08 Feb 2023 //
GLOBENEWSWIRE
T-knife Therapeutics Announces Dosing of First Patient with TK-8001
20 Oct 2022 //
GLOBENEWSWIRE
T-knife Therapeutics Announces New TCR-T Program Targeting KRAS G12V at AACR
08 Apr 2022 //
GLOBENEWSWIRE
T-knife Therapeutics Announces $110 Million Series B Financing
02 Aug 2021 //
GLOBENEWSWIRE
T-knife bags $110M for raft of cell therapy solid tumor trials
02 Aug 2021 //
FIERCEBIOTECH
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.